BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29191657)

  • 21. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
    Boudou-Rouquette P; Tlemsani C; Blanchet B; Huillard O; Jouinot A; Arrondeau J; Thomas-Schoemann A; Vidal M; Alexandre J; Goldwasser F
    Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1433-1444. PubMed ID: 27556889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series.
    Yoo KH; Kim HS; Lee SJ; Park SH; Kim SJ; Kim SH; La Choi Y; Shin KH; Cho YJ; Lee J; Rha SY
    BMC Cancer; 2015 Mar; 15():154. PubMed ID: 25885855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
    Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
    J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line.
    Joyner DE; Albritton KH; Bastar JD; Randall RL
    J Orthop Res; 2006 Mar; 24(3):474-80. PubMed ID: 16450387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor.
    Su L; Cheng H; Sampaio AV; Nielsen TO; Underhill TM
    Oncogene; 2010 Jul; 29(30):4352-61. PubMed ID: 20514024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.
    Bupathi M; Hays JL; Chen JL
    PLoS One; 2017; 12(11):e0188116. PubMed ID: 29141017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.
    Terry J; Lubieniecka JM; Kwan W; Liu S; Nielsen TO
    Clin Cancer Res; 2005 Aug; 11(15):5631-8. PubMed ID: 16061882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct mechanisms of microRNA sorting into cancer cell-derived extracellular vesicle subtypes.
    Temoche-Diaz MM; Shurtleff MJ; Nottingham RM; Yao J; Fadadu RP; Lambowitz AM; Schekman R
    Elife; 2019 Aug; 8():. PubMed ID: 31436530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.
    O'Brien K; Lowry MC; Corcoran C; Martinez VG; Daly M; Rani S; Gallagher WM; Radomski MW; MacLeod RA; O'Driscoll L
    Oncotarget; 2015 Oct; 6(32):32774-89. PubMed ID: 26416415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
    Ishibe T; Nakayama T; Okamoto T; Aoyama T; Nishijo K; Shibata KR; Shima Y; Nagayama S; Katagiri T; Nakamura Y; Nakamura T; Toguchida J
    Clin Cancer Res; 2005 Apr; 11(7):2702-12. PubMed ID: 15814652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tailored therapeutic strategies for synovial sarcoma: receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001.
    Yasui H; Naka N; Imura Y; Outani H; Kaneko K; Hamada K; Sasagawa S; Araki N; Ueda T; Itoh K; Myoui A; Yoshikawa H
    Cancer Lett; 2014 May; 347(1):114-22. PubMed ID: 24491407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extracellular Vesicles and MicroRNAs: Their Role in Tumorigenicity and Therapy for Brain Tumors.
    Bronisz A; Godlewski J; Chiocca EA
    Cell Mol Neurobiol; 2016 Apr; 36(3):361-76. PubMed ID: 26983830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Commitment of Annexin A2 in recruitment of microRNAs into extracellular vesicles.
    Hagiwara K; Katsuda T; Gailhouste L; Kosaka N; Ochiya T
    FEBS Lett; 2015 Dec; 589(24 Pt B):4071-8. PubMed ID: 26632510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck.
    Olsen RJ; Lydiatt WM; Koepsell SA; Lydiatt D; Johansson SL; Naumann S; Bridge JA; Neff JR; Hinrichs SH; Tarantolo SR
    Head Neck; 2005 Oct; 27(10):883-92. PubMed ID: 16158422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of TRIP6 promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR) via regulating nuclear p27(Kip1) expression in non-Hodgkin's lymphoma.
    Miao X; Xu X; Wu Y; Zhu X; Chen X; Li C; Lu X; Chen Y; Liu Y; Huang J; Wang Y; He S
    Tumour Biol; 2016 Jan; 37(1):1369-78. PubMed ID: 26298725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ).
    Horiuchi K; Morioka H; Nishimoto K; Suzuki Y; Susa M; Nakayama R; Kawai A; Sonobe H; Takaishi H; Ozaki T; Yabe H; Umezawa K; Toyama Y
    Cancer Lett; 2008 Dec; 272(2):336-44. PubMed ID: 18760530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extracellular vesicles from bone marrow mesenchymal stem/stromal cells transport tumor regulatory microRNA, proteins, and metabolites.
    Vallabhaneni KC; Penfornis P; Dhule S; Guillonneau F; Adams KV; Mo YY; Xu R; Liu Y; Watabe K; Vemuri MC; Pochampally R
    Oncotarget; 2015 Mar; 6(7):4953-67. PubMed ID: 25669974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid and fatal acute heart failure induced by pazopanib.
    van Marcke C; Ledoux B; Petit B; Seront E
    BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26336188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis.
    Katz D; Azraq Y; Eleyan F; Gill S; Peretz T; Merimsky O
    BMC Cancer; 2016 Aug; 16():616. PubMed ID: 27501793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.